Atopic Dermatitis: Targeting Underlying Inflammatory Pathways with Systemic Therapy THE THRIVE INITIATIVE
Course Evaluation Survey
What is your specialty focus?
What is your type of practice?
How many years have you been in practice?
Fewer than 5
5 to 9
10 to 15
More than 15
Please estimate the number of patients with moderate-to-severe atopic dermatitis you provide for weekly:
Fewer than 5
Were the following learning objectives met? (Please check appropriate rating)
Apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with atopic dermatitis during the COVID-19 pandemic
Assess the severity of atopic dermatitis and select appropriate treatment options for patients who require intensified therapy
Review the mechanism of action, efficacy and safety of systemic treatments for atopic dermatitis in pediatric and adult patients
Please rate your confidence in ability to diagnose, treat, and manage moderate-to-severe atopic dermatitis on a scale of 1 to 5, where 1 means “Not confident at all” and 5 means “Very Confident.”
Not confident at all
As a result of this course, I will likely make changes to my practice:
If YES, in which of the following categories? (Please check all that apply)
Coordination of care
Patient communication/ education
In particular, as a result of this course, I will be more likely to implement the following changes (Please check all that apply):
I am more likely to assess the mental and social impact of AD when selecting treatment options.
I am more likely to identify patients with AD who require intensified therapy.
I am more likely to incorporate treatment guidelines and clinical trial data into treatment plans for adult and pediatric patients with moderate-to-severe disease.
I am more likely to consider a patient's risk of severe COVID-19 when initiating systemic therapy.
Additionally, I will change:
What barriers may prevent/inhibit changes in practice recommended in this activity?
Number of Patients
Did you view the animations offered in this program?
If YES, how do you feel the animations impacted your learning? (Please check all that apply)
Improved ability to assess the severity of atopic dermatitis and intensify therapy appropriately
Improved ability to select treatment options for adult and pediatric patients based on an understanding of the efficacy and safety of systemic treatments
Improved ability to apply up-to-date guidance on the initiation and use of systemic immunosuppressants and immunomodulators in patients with AD during the COVID-19 pandemic
Will improve recall of lessons learned
Will improve dialogue with patients
Will improve ability to individualize treatment
Please evaluate this activity as a whole. (Please check appropriate rating)
The learning format was interactive and engaging.
The content was pertinent to my professional needs.
The activity will ultimately benefit patient care.
I would recommend this activity to colleagues.
Do you feel a commercial product, device, or services was inappropriately promoted in this educational activity?
If YES, please comment:
What was the most effective aspect(s) of this learning activity?
Do you have suggestions for improving the session or topics for future activities?
New and emerging therapies
Other treatment modalities
Coordination of care
Please evaluate the faculty (Please check appropriate rating)
Donald Leung, MD
Peter Lio, MD
Thank you. Any additional comments are welcome below.
If you have any concerns you would like to discuss, please email us at firstname.lastname@example.org. To better understand the value of this program, MLG may contact you with a follow-up survey. This survey is designed to assess the value of the program and measure any behavior change. We truly appreciate your participation.
Yes, Med Learning Group has my permission to fax or email information to me about further programs.